SAN FRANCISCO and SUZHOU, China, May 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...
Hence then, the article about innovent announces oral presentation of full phase 2 clinical data for efdamrofusp alfa ibi302 first in class anti vegf complement bispecific fusion protein at arvo 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 )
Also on site :
- Guitar Center is dropping its ban on playing ‘Stairway to Heaven.’ It’s part of the CEO’s big turnaround plan
- Pentagon to livestream firing-squad execution of US Army psychiatrist who killed 13 in 2009 attack: Inside the scrutinized plan
- Vietnamese Horror ‘Arithmadtic’ Leads Bee Entertainment’s Busan Market Slate, With New Film From ‘The Corpse’ Director